#USA #National Harbor, Maryland #CAR therapy #CREATE Medicines #MT-302

CREATE Medicines to Present Late-Breaking Clinical Data on MT-302

CREATE Medicines, Inc., formerly known as Myeloid Therapeutics, has announced an exciting development in their clinical trials at the upcoming Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting. This prestigious event will take place from November 5 to 9, 2025, in National Harbor, Maryland. A significant highlight at this meeting will be the late-breaking oral presentation of findings from the Phase 1 MYE Symphony trial, which evaluates their investigational therapy MT-302.

Overview of MT-302

MT-302 represents a pioneering advance in cancer treatment, specifically targeting solid tumors—conditions that have traditionally been challenging for CAR (chimeric antigen receptor) therapies. According to Dr. Matt Maurer, Chief Medical Officer at CREATE Medicines, the preliminary results indicate that their unique in vivo immune programming can potentially address the deep-rooted limitations that have historically confined CAR therapies to treating only blood cancers. This exciting approach could redefine the treatment landscape for patients suffering from solid tumors, offering them access to effective, systemic therapies without facing the usual complexities and financial barriers associated with traditional cell therapy.

How MT-302 Works

The design of MT-302 is innovative, employing mRNA-LNP (lipid nanoparticle) technology to elicit an adaptive immune response against solid tumors. By delivering the therapy systemically via its mRNA-LNP platform, CREATE Medicines effectively programs the immune system to identify and target solid tumors expressing TROP2. The therapy encodes a TROP2-specific CAR, enabling selective reprogramming of myeloid cells to fight cancer more effectively. This approach eliminates the need for cumbersome ex vivo manipulations and preconditioning, allowing for repeat dosing and adaptable CAR expression, which can enhance anti-tumor activity dramatically.

Presentation Details

During the SITC Annual Meeting, details surrounding the clinical study will be disclosed, emphasizing its implications for future cancer therapies. Dr. Rasha Cosman from The Kinghorn Cancer Centre in Darlinghurst, NSW, Australia, will present the findings under the oral abstract category, specifically in Clinical Oral Abstract Session 1. The session is slated for November 7, 2025, from 11:30 AM to 12:15 PM ET at the Gaylord National Resort & Convention Center, Potomac Ballroom.

The abstract, numbered LBA 1342, will shed light on vital aspects such as the safety, pharmacokinetics, pharmacodynamics, and initial efficacy of this novel mRNA-LNP therapy. With preliminary data pointing towards promising results, CREATE Medicines is optimistic about the potential to change the standard of care for many cancer patients.

Looking Ahead

Following the presentation, additional insights will be made publicly available on the SITC website after the embargo is lifted on November 7, 2025, at 9:00 AM ET. CREATE Medicines continues to be steadfast in its commitment to innovation in the biotech space, seeking to transform cancer treatment paradigms.

For more information on CREATE Medicines and future developments, please visit their website at createmedicines.com. Updates will also be shared on their LinkedIn and X (formerly Twitter) channels as they work towards revolutionizing cancer therapies to improve patient outcomes despite existing challenges in this arena.